STAT

JULY 11, 2024

Food and Drug Administration rejected Novo Nordisk’s weekly insulin for treating diabetes in a rare setback for the company , STAT tells us. Novo said it does not expect to be able to fulfill the requests during 2024, delaying the program for several months at least.

Diabetes 293

Diabetes Packaging 293

Pharmaceutical Technology

SEPTEMBER 10, 2024

The study involved over 3,600 participants, including FDRs of newly diagnosed type 1 diabetes patients in Denmark and children in Sweden.

Diabetes 97

Diabetes 97

STAT

APRIL 23, 2024

Soaring demand for diabetes and obesity drugs has led to shortages for Lilly and Novo Nordisk. Food and Drug Administration’s website showed most doses of Lilly’s diabetes drug Mounjaro and weight loss drug Zepbound would be in limited supply through the second quarter of this year. Last week, the U.S.

Diabetes 286

Diabetes 286

pharmaphorum

JANUARY 15, 2025

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

Diabetes 97

Diabetes 97

European Pharmaceutical Review

DECEMBER 5, 2023

billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes.

Diabetes 110

Diabetes 110

PharmExec

NOVEMBER 14, 2023

Novo Nordisk said it will continue providing Levemir vials and the Levemir FlexPen for diabetes control while supplies last, until the full product discontinuation at the end of 2024.

Diabetes 97

Diabetes 97

Express Pharma

DECEMBER 31, 2024

On December 20, 2024, tirzepatide also received FDA approval for obstructive sleep apnea. Indeed, semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors, and is in development for four additional indications, including chronic kidney disease. While Wegovy caused an average weight loss of 13.7

Diabetes 105

Diabetes 105

BioPharma Dive

JANUARY 14, 2025

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.

Diabetes 123

Diabetes 123

pharmaphorum

JULY 12, 2021

Bayer’s big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition in the market. . Bayer’s FINEARTS-HF trial of Kerendia in HFpEF started last year and isn’t due to generate results until 2024.

Diabetes 98

Diabetes 98

Express Pharma

AUGUST 16, 2024

The biopharmaceutical industry remained resilient in the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve. trillion as on 31 March 2024 to $4 trillion as on 30 June 2024, reveals GlobalData. AstraZeneca reported a 15.5

Diabetes 98

Diabetes Immunity Immunization Vaccines 98

STAT

OCTOBER 24, 2023

Sanofi and NovoNordisk will lower their prices as of January 2024; Lilly reduced it to $35 per month in March 2023.) Following two decades of sharp increases for consumers, the companies vowed to cut insulin prices for some insulins by at least 70%, meaning many people could see their insulin costs capped at $35 a month in the near future.

Pharmaceutical Companies 345

Pharmaceutical Companies Pharmaceutical Companies Diabetes 345

STAT

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments , STAT writes. The … Under mounting pressure, Novo Nordisk plans to cut U.S.

Diabetes 246

Diabetes 246

STAT

JANUARY 31, 2024

 The announcement concerning the lower-dose starter product came as the company reported 2023 sales rose 36% and operating profit grew 44% at constant exchange rates, driven by massive sales of Wegovy and Ozempic, used to treat diabetes. Novo also projected double-digit growth in sales and operating profit for 2024.

Diabetes 286

Diabetes 286

STAT

OCTOBER 27, 2023

The plan is to increase investment in its drug-development pipeline and cut costs, and the split could take place as early as the fourth quarter of 2024. The panel committee reviewed non-clinical, clinical, and post-marketing data of the drugs, and said that no updates to their prescribing information was required at the time.

Diabetes 300

Diabetes Drug Development 300

European Pharmaceutical Review

MARCH 8, 2024

Approximately 40 percent of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.”

Diabetes 98

Diabetes Labelling 98

Pharmaceutical Technology

SEPTEMBER 12, 2024

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.

Diabetes 98

Diabetes 98

The Pharmacist

JANUARY 3, 2024

Supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is not expected to return to normal until at least the end of 2024, the government has confirmed.

Diabetes 115

Diabetes 115

STAT

DECEMBER 1, 2023

Data are expected in the first half of 2024. Both medicines are GLP-1 agonists, a class originally designed to treat type 2 diabetes. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Diabetes 285

Diabetes Hospitals 285

pharmaphorum

AUGUST 9, 2024

Eli Lilly raises guidance for 2024 by $3 billion on strong growth for tirzepatide in diabetes and obesity and improved supply capacity

Diabetes 117

Diabetes 117

Express Pharma

FEBRUARY 11, 2024

In January 2024, the healthcare industry reported 88 deals worth $13.8 per cent of the total deal value during January 2024. per cent in Jan 2024, compared to Jan 2023 The healthcare industry reported 135 venture capital (VC) deals worth $2.8 These were the three major VC deals reported in January 2024.

Diabetes 109

Diabetes 109

pharmaphorum

AUGUST 17, 2021

Data from phase 3 trials of the drug in diabetic macular oedema (DMO) provide some encouragement for Novartis on the safety issue, with Beovu (brolucizumab) found to be roughly equivalent to Bayer and Regeneron’s Eylea (aflibercept) when it came to inflammatory reactions in the eye. of Beovu patients, compared to 1.7%

Diabetes 98

Diabetes Biosimilars 98

STAT

AUGUST 10, 2023

supplies of starter doses of its hugely popular Wegovy weight-loss drug, most likely into 2024, as the company struggles to keep up with soaring U.S. The company is riding a wave of sky-high demand for its highly effective diabetes and weight-loss drugs, Ozempic and Wegovy, but will extend the limits introduced for Wegovy supplies.

Drug Pricing 245

Drug Pricing Diabetes 245

STAT

APRIL 24, 2024

Biogen reaffirmed its 2024 guidance. Leqembi sales of $19 million were also better than the lowered expectations, with a “significant increase” in new patient starts seen in March. Adjusted earnings were $3.67 on total revenue of $2.29 Roche also reported  first quarter earnings.

Diabetes 321

Diabetes 321

Express Pharma

SEPTEMBER 20, 2023

Eli Lilly received approval for its dual glucagon-like peptide-1 receptor agonist (GLP-1)/gastric inhibitor polypeptide receptor agonist (GIP) therapy Mounjaro (tirzepatide) in August 2023 for use as a new treatment option for patients in England with type 2 diabetes (T2D), in cases where the existing treatment management options are insufficient.

Diabetes 105

Diabetes 105

Pharmaceutical Technology

MAY 3, 2024

Despite failing to get an approval for type 1 diabetes in 2019, Lexicon plans to resubmit its NDA to the FDA by mid-2024.

Diabetes 59

Diabetes 59

STAT

SEPTEMBER 4, 2024

Intermittent shortages of the diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states , Reuters writes. Investors had expected that on some serotypes the vaccines had in common, Prevnar would do better.

Vaccines 161

Vaccines Diabetes 161

Express Pharma

MAY 15, 2024

Based on our 2023 survey, we anticipate a significant increase in the adoption of pharmacy-provided services such as diagnostic services, health screenings, home delivery of medicine, and medication therapy management for chronic illnesses such as hypertension and diabetes (see Fig 4).

Health and Personal Care Stores 107

Health and Personal Care Stores Hospitals Diabetes Inpatient 107

pharmaphorum

APRIL 13, 2022

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide and dulaglutide.

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Diabetes 52

Diabetes 52

Pharmaceutical Technology

SEPTEMBER 10, 2024

At EASD 2024, meta-analysis results shed new light on the genetic transmission of type 1 diabetes (T1D) from parents to offspring.

Diabetes 52

Diabetes 52

Pharmacy Times

NOVEMBER 14, 2024

The 2024 American Heart Association and American Stroke Association stroke prevention guidelines recommend glucagon-like peptide-1 receptor agonists to reduce the risk of stroke in individuals with diabetes and high cardiovascular risk.

Diabetes 55

Diabetes 55

Express Pharma

JANUARY 14, 2025

Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. per cent from 2024 to 2030. billion in 2023 and is expected to grow at a CAGR of 8.4 Whereas the global vitamin supplements market size was estimated at $48.51 per cent from 2023 to 2030.

Diabetes 105

Diabetes Compounding 105

Drug Channels

MAY 16, 2024

They discussed new GoodRx research and had a candid discussion about their daily challenges in caring for patients—especially those living with diabetes and obesity. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Click here to watch the full video of the conversation between Drs.

Diabetes 52

Diabetes 52

ALiEM - Pharm Pearls

OCTOBER 30, 2024

2024 study [16]. Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. 2024 Oct 8:S0735-6757(24)00523-0. Published online September 4, 2024. 2024.10.006].

HIV Treatment and Prevention Agents 161

HIV Treatment and Prevention Agents Inpatient Hospitals Diabetes 161

Pharmafile

JANUARY 18, 2023

A new app, designed by researchers at Oregon Health & Science University (OSHU), uses artificial intelligence (AI) to assess blood sugar levels as concerning trends, as well as suggesting management tools, is set to become part of a clinical trial in 2024. read more.

Diabetes 59

Diabetes Communication 59

Big Molecule Watch

AUGUST 6, 2024

The Committee for Medicine Products for Human Use (“CHMP”) recommended 14 medicines for European Medicines Agency Approval (“EMA”) approval (“marketing authorization”), during its monthly meeting on July 22-25, 2024. The post EU Committee Recommends Approval of 6 New Biosimilars in July 2024 Meeting appeared first on Big Molecule Watch.

Biosimilars 59

Biosimilars Diabetes 59

Express Pharma

JUNE 20, 2024

The World Health Organisation on June 21, 2024 (Thursday) issued warnings on fake drugs claiming to contain the active ingredient found in Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Wegovy.

Diabetes 103

Diabetes 103